The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
Open accessAbstract
There is consensus that an optimized cancer vaccine will have to induce not only CD8+ cytotoxic but also CD4+ T helper (Th) cells, particularly interferon (IFN)-γ–producing, type 1 Th cells. The induction of strong, ex vivo detectable type 1 Th cell responses has not been reported to date. We demonstrate now that the subcutaneous injection of cryopreserved, mature, antigen-loaded, monocyte-derived dendritic cells (DCs) rapidly induces unequivocal Th1 responses (ex vivo detectable IFN-γ–producing effectors as well as proliferating precursors) both to the control antigen KLH and to major histocompatibility complex (MHC) class II–restricted tumor peptides (melanoma-antigen [Mage]-3.DP4 and Mage-3.DR13) in the majority of 16 evaluable patients with metastatic melanoma. These Th1 cells recognized not only peptides, but also DCs loaded with Mage-3 protein, and in case of Mage-3DP4–specific Th1 cells IFN-γ was released even after direct recognition of viable, Mage-3–expressing HLA-DP4+ melanoma cells. The capacity of DCs to rapidly induce Th1 cells should be valuable to evaluate whether Th1 cells are instrumental in targeting human cancer and chronic infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Self-citationKinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells
Langenkamp, A., Messi, M., Lanzavecchia, A., & Sallusto, F. (2000) · Nature Immunology · doi:10.1038/79758 · Cited by 1,143
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M.-F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665
Kaliński, P., Hilkens, C. M., Snijders, A., Snijdewint, F. G., & Kapsenberg, M. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.28 · Cited by 602
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Cited by
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
Lutz, M. B., & Schuler, G. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02281-0 · Cited by 1,349
Self-citationEscudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Dendritic cells as therapeutic vaccines against cancer
Banchereau, J., & Palucka, A. K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1592 · Cited by 1,204
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Dendritic cell immunotherapy: mapping the way
Figdor, C. G., de Vries, I. J. M., Lesterhuis, W. J., & Melief, C. J. M. (2004) · Nature Medicine · doi:10.1038/nm1039 · Cited by 945
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2173 · Cited by 750
Fujii, S.-I., Shimizu, K., Smith, C., Bonifaz, L., & Steinman, R. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030324 · Cited by 711
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
The use of dendritic cells in cancer immunotherapy
Schuler, G., Schuler-Thurner, B., & Steinman, R. M. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00015-3 · Cited by 631
Self-citationThe liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Inflammatory signals in dendritic cell activation and the induction of adaptive immunity
Joffre, O., Nolte, M. A., Spörri, R., & Sousa, C. R. E. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00718.x · Cited by 598
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
Zhou, R., To, K. K.-W., Wong, Y.-C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.-Y., Lau, T. T.-K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.026 · Cited by 531
Schadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F. O., Enk, A., Bröcker, E.-B., Grabbe, S., Rittgen, W., Edler, L., Sucker, A., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj138 · Cited by 467
Self-citationViaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
CD4 cells can be more efficient at tumor rejection than CD8 cells
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 437
Dendritic cell subsets in health and disease
Ueno, H., Klechevsky, E., Morita, R., Aspord, C., Cao, T., Matsui, T., Di Pucchio, T., Connolly, J., Fay, J. W., Pascual, V., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00551.x · Cited by 430
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 377
From genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
Manipulating dendritic cell biology for the active immunotherapy of cancer
O'Neill, D. W., Adams, S., & Bhardwaj, N. (2004) · Blood · doi:10.1182/blood-2003-12-4392 · Cited by 339
Rossi, M., & Young, J. W. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1373 · Cited by 338
Eigentler, T. K., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 324
Epitope-based vaccines: an update on epitope identification, vaccine design and delivery
Sette, A., & Fikes, J. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00083-9 · Cited by 322
Some interfaces of dendritic cell biology
STEINMAN, R. M. (2003) · APMIS · doi:10.1034/j.1600-0463.2003.11107802.x · Cited by 292
The First 1000 Dendritic Cell Vaccinees
Ridgway, D. (2003) · Cancer Investigation · doi:10.1081/cnv-120025091 · Cited by 278
Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26365 · Cited by 70
Metadata
- Authors
- Schuler-Thurner, B., Schultz, E. S., Berger, T. G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Feuerstein, B., Fritsch, P. O., Romani, N., & Schuler, G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-05-13
- Volume
- 195
- Issue
- 10
- Pages
- 1279-1288
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2095825164
- Cited by
- 475
- References
- 33
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.